Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE1702 in Advanced or Metastatic HER2-expressing Solid Tumors
NCT04319757Phase 1Completed
- Sponsor
- Acepodia
- Start
- Jun 2020
- Primary completion
- Jul 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of ACE1702 in HER2-positive solid tumor, HER2-positive gastric cancer and HER2-positive breast cancer (6 arms), sponsored by Acepodia. Primary endpoints: Adverse Events, including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs) and Phase Ib/II starting dose for ACE1702. Started Jun 2020; status: completed.
02
Drugs
ACE1702
03
Conditions
HER2-positive solid tumorHER2-positive gastric cancerHER2-positive breast cancer
Beyond the preview
Go deeper on NCT04319757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319757.